Funso Kumolu
Tells us who owns the data and who’s permitted to use it.
DATA RIGHTS
CSI tracks and manages the data rights of our 600+ TERABYTES of data to ensure we are accessing the right data from the right clients for the right purposes.
A credit-based replenishment model eliminates this common 340B inventory problem.
INVENTORY SWELL
McKesson’s VRR and LoopRx products prevent inventory swell by recognizing retail purchases that are already made by the pharmacy.
Specialty leakage product launched via MomentimRx.
VELOCITY
A leakage analytics solution designed to help health systems retain scripts. As the second product launched through MomentimRx, Velocity is estimated to deliver $10M AOP this year.
This team’s theme song should be BTO’s “Takin’ Care of [THE] Business”
CSI FINANCE PARTNERS
Innovation results in new products for our customers and for McKesson, requiring us to evolve how we think about, measure and track value. Our Finance Partners have been key to this innovation evolution.
Customer program that has identified $250M+ in savings.
BUYSMARTER
BuySmarter leverages AI-driven insights, and inventory and cost management, to deliver real-time savings to customers. It's created over $100M in incremental margin for McKesson.
On January 1, 2026, 340B up-front discounts will be replaced by this model.
340b REBATE MODEL
Entities will purchase drugs at a higher price (WAC), then receive a manufacturer rebate to bring the final cost down to the 340B ceiling price.
Initiative to improve contract transparency and communication loops for VA customers.
DENALI
Once fully implemented, this product will enhance VA contract efficiency and compliance by automating contract changes and product updates.
This McKesson business processes >1M prescriptions per day helping patients get the meds they need.
MCKESSON PHARMACY SYSTEMS
Our industry-leading pharmacy management system, EnterpriseRx, helps alleviate manual tasks, manage workload balancing across pharmacies, and simplify daily operations.
Data feed responsible for our primary competitive pricing and sourcing intelligence.
PEGASYS
Sourced from EnterpriseRx, Liberty and Macro Helix, this data allows us to predict market events and claw back identified leakage.
Federal legislation projected to result in millions of Americans becoming uninsured over the next decade.
ONE BIG BEAUTIFUL BILL (HR1)
Rising costs and reduced reimbursement are making healthcare transformation inevitable, representing an opportunity for us to develop & deliver creative solutions for our customers.
Initiative to define the strategy for a unified ordering platform for PSaS
MULAN
By addressing customer pain points caused by fragmented systems, it aims to streamline the digital experience, improve operational efficiency, and strengthen customer engagement.
This report outlines the value generated by CSI for the enterprise.
CSI QUARTERLY VALUE REPORT
CSI exists to support all of USPD. We do so by generating and capturing measurable value by enabling solutions to the USPD segments. We report this value quarterly.
The average number of searches on Connect each day.
200,000
Search results are a key driver in converting customers from one equivalent product to another.
Consolidation of entities within the pharmaceutical supply chain.
VERTICAL INTEGRATION
Vertical Integration (like 340B contract pharmacies integrated with a PBM) is driving questions about pricing transparency, a trend we’ll continue to watch.
A digitally-native approach to product development.
TECHNICAL PRODUCT MANAGEMENT
Our organizational shift to a more technical product approach will accelerate responsiveness, moving us from delivering in weeks and months, vs quarters and years.
WINE & SPIRITS
It is critical for us to continue to stay focused on the topics and the work where we have the right to play, and to make a difference in the lives of others.
The average time a Connect order is placed after the initial search.
2 DAYS
Getting teams connected to this information is an early signal for demand. We leverage this data to improve the resilience of our supply chain.
The highest increase in 15 years to health benefit costs is attributed (in part) to this group of drugs.
GLP-1s
Pharmacy costs account for ~25% of healthcare spending. GLP-1 drugs are a significant recent driver of this, with a total of 10 FDA-approved drugs covering 8 different indications.
McKesson’s TPA-agnostic virtual credit-based replenishment solution.
LOOPRX
McKesson’s TPA-agnostic virtual credit-based replenishment solution for 340B customers, the first generally available product commercialized through MomentimRx.
This pop hit evolved from a reggae song called “Never Stop”
START ME UP
CSI is like the song in two key ways: 1.) We aim to function with speed & agility, like a start-up. 2.) We are continually evolving our approach to the work.